Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma

Sullivan, David; A. Gebo, Kelly; Shoham, Shmuel; M. Bloch, Evan; Lau, Bryan; Shenoy, Aarthi; Mosnaim, Giselle; J. Gniadek, Thomas; Fukuta, Yuriko; Patel, Bela; L. Heath, Sonya; C. Levine, Adam; Meisenberg, Barry; S Spivak, Emily; Anjan, Shweta; A. Huamán, Moisés; E. Blair, Janis; S. Currier, Judith; H. Paxton, James; M. Gerber, Jonathan; Petrini, Joann; Broderick, Patrick; Rausch, William; Elena Cordisco, Marie; Hammel, Jean; Greenblatt, Benjamin; Cluzet, Valerie; Cruser, Daniel; Oei, Kevin; Abinante, Matthew; L. Hammitt, Laura; G. Sutcliffe, Catherine; N. Forthal, Donald; S. Zand, Martin; R. Cachay, Edward; S. Raval, Jay; Kassaye, Seble; Foster, Emily; D. Roth, Michael; E. Marshall, Christi; Yarava, Anusha; Lane, Karen; McBee, Nichol; L. Gawad, Amy; Karlen, Nicky; Singh, Atika; E. Ford, Daniel; A. Jabs, Douglas; J. Appel, Lawrence; Shade, David; Ehrhardt, Stephan; Baksh, Sheriza; Laeyendecker, Oliver; Pekosz, Andrew; L. Klein, Sabra; Casadevall, Arturo; A.R. Tobian, Aaron; F. Hanley, Daniel

doi:10.1101/2021.12.10.21267485

Public

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma

Published in medRxiv • Dec 21, 2021

Authors:

David Sullivan

Kelly A. Gebo

Shmuel Shoham

Abstract

BACKGROUND: The efficacy of polyclonal high titer convalescent plasma to prevent serious complications of COVID-19 in outpatients with recent onset of illness is uncertain. METHODS: This multicenter, double-blind randomized controlled trial compared the efficacy and safety of SARS-CoV-2 high titer c...

Subject

Medicine

Clinical endpoint

Titer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!